Page 21 - ITPS-6-1

15
INNOSC Theranostics and Pharmacological Sciences 2023 Vol. 6 (No. 1) pp: 15-21

INNOSC Theranostics and Pharmacological Sciences

Journal homepage: https://accscience.com/journal/ITPS

REVIEW ARTICLE
Impact of COVID-19 Pandemic on Cancer Patients with Pulmonary

Fibrosis on Chemosurveillance

Kiran R. Dudhat*

Department of Pharmaceutics, School of Pharmacy, RK University, Kasturbadham, Rajkot, Gujarat, India
*Corresponding Author: Kiran Rameshbhai Dudhat, Email: kichupatel@gmail.com
Received: November 8, 2022; Accepted: March 21, 2023; Published: April 3, 2023 DOI: 10.36922/itps.252
Copyright: Author(s). This is an open-access article distributed under the terms of the Attribution Non-Commercial 4.0 International
4.0 (CC BY-NC 4.0), which permits all non-commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited.

Abstract:

COVID-19 infection and multiplication can be regulated with the aid of vaccines, immunosurveillance, and antiviral medications,
such interferon and nucleoside analogs. The main concern with COVID-19 infection is the proliferation of the virus. However,
there is no medication to treat pulmonary fibrosis, a life-threatening condition, once it has manifested. To treat critically ill patients
with cancer and pulmonary fibrosis, it is imperative to develop cell differentiation agent (CDA) formulations that can kill cancer
stem cells. Chemosurveillance for cancer patients no longer functions as intended. As a result, people with cancer are more likely
to experience severe symptoms of pulmonary fibrosis. The harm to chemosurveillance caused by cancer treatments that focus on
cell death, such as cytotoxic drugs, radiation, and immunotherapy, may gravely accelerate the development of fatal pulmonary
fibrosis. To prevent the development of fatal pulmonary fibrosis symptoms, cancer patients should be advised against contracting
COVID-19, but, if they do, targeted therapy should be their first choice. The purpose of this study was to highlight the significance
of chemosurveillance in determining when fatal pulmonary fibrosis manifests after COVID-19 infection in cancer patients and
to conceptualize CDA formulations that can be used to treat both pulmonary fibrosis and cancer. COVID-19 infection causes
biological and immunological reactions that are similar to those of a wound, leading to the production of prostaglandins and tumor
necrosis factor, which cause respiratory illness symptoms, such as fever and cough, and cachexia symptoms, respectively. This
results in the breakdown of chemosurveillance, a natural defense mechanism that ensures optimal wound healing, thus further
promoting the development of cancer and pulmonary fibrosis.

Keywords: Cancer, COVID-19, Cell differentiation agent formulations, Chemosurveillance, Pulmonary fibrosis, Wound healing

1. Introduction vaccinations significantly slowed the spread of the
pandemic. However, the rapid development of viral
In December 2019, the COVID-19 pandemic variations has led to the COVID-19 pandemic’s
began in China and swiftly spread to other nations, incessant spread in successive waves [2].
resulting in 6.34 million confirmed deaths and 571 Immunosurveillance, vaccinations and antiviral
million confirmed cases worldwide as of August medications such as interferon and nucleoside
2022 [1,2]. Most individuals suffered either directly analogues can all slow the growth of COVID-19.
from infection or indirectly as a result of restrictions Lung fibrosis, as the primary cause of death
on public gatherings. The COVID-19 infection from COVID-19 infection, is not yet treatable
may result in deadly pulmonary fibrosis and severe with medication. If pulmonary fibrosis can
acute respiratory syndrome [3]. The development of be successfully treated, COVID-19 might not

©2023 AccScience Publishing